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http://dx.doi.org/10.1016/j.ccr.2014.03.036SUMMARYEvidence for distinct human cancer stem cells (CSCs) remains contentious and the degree to which
different cancer cells contribute to propagating malignancies in patients remains unexplored. In low- toSignificance
Experimental evidence supporting the existence of human cancer stem cells (CSCs) remain extensively contested and
in vivo fate mapping of candidate human CSCs in patients has not been possible. Through establishment of molecularly
and functionally distinct and hierarchically organized stem and progenitor cell compartments in myelodysplastic
syndromes (MDS) and backtracking of identified somatic genetic lesions, we establish that rare LinCD34+CD38CD90+
CD45RAMDS cells function as MDS-propagating cells in patients with low- to intermediate-risk MDS. Because their elim-
ination will be essential, and possibly also sufficient, toward eradication of the entire MDS clone, the definitive identification
of rare but distinct MDS stem cells will now facilitate development of therapies specifically targeting MDS stem cells.
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Rare MDS-Propagating Cancer Stem Cells In Vivointermediate-risk myelodysplastic syndromes (MDS), we establish the existence of rare multipotent MDS
stem cells (MDS-SCs), and their hierarchical relationship to lineage-restricted MDS progenitors. All identified
somatically acquired genetic lesions were backtracked to distinct MDS-SCs, establishing their distinct MDS-
propagating function in vivo. In isolated del(5q)-MDS, acquisition of del(5q) preceded diverse recurrent driver
mutations. Sequential analysis in del(5q)-MDS revealed genetic evolution in MDS-SCs and MDS-progenitors
prior to leukemic transformation. These findings provide definitive evidence for rare humanMDS-SCs in vivo,
with extensive implications for the targeting of the cells required and sufficient for MDS-propagation.INTRODUCTION
The concept that human cancers might be propagated exclu-
sively by rare self-renewing cancer stem cells (CSCs), replenish-
ing nontumorigenic cancer cells, has extensive implications for
the development of targeted cancer therapies (Clevers, 2011;
Magee et al., 2012). Whereas the existence of cells with human
CSC-potential has been supported experimentally in some
hematological malignancies (Bonnet and Dick, 1997; Goardon
et al., 2011; Jamieson et al., 2004; Nilsson et al., 2000) and solid
tumors (Al-Hajj et al., 2003; Schatton et al., 2008), the CSC
concept has recently been contested in mouse and man
(reviewed in Clevers, 2011; Magee et al., 2012) through multiple
studies suggesting that cells with CSC potential, including
leukemic stem cells (LSCs), might be neither rare (Kelly et al.,
2007; Quintana et al., 2008) nor phenotypically or molecularly
distinct (le Viseur et al., 2008; Quintana et al., 2008). Of particular
relevance, compelling evidence has demonstrated significant,
intrinsic limitations of existing human CSC and LSC in vivo as-
says (Clevers, 2011; Kelly et al., 2007; Magee et al., 2012; Taus-
sig et al., 2008), failing to reveal the cancer-propagating potential
of investigated cancer cell populations as illustrated by a large
fraction of patients with acute myeloid leukemia (AML) having
no leukemic cells reading out in LSC assays (Pearce et al., 2006).
Regardless, in vitro or in vivo CSC/LSC assays cannot estab-
lish to what degree different cancer cells act to propagate the
cancer in patients, which ultimately is the most biologically and
clinically relevant CSC property. Proposed identities of human
CSCs/LSCs therefore await definitive verifications in patients
(Clevers, 2011; Magee et al., 2012), although it will be difficult
to apply the genetically engineered lineage-tracing technologies
in human malignancies, which recently allowed the definitive
identification and fate-mapping of mouse CSCs in vivo (Chen
et al., 2012; Driessens et al., 2012; Schepers et al., 2012).
Myelodysplastic syndromes (MDS) are clonal hematopoietic
disorders characterized by inefficient hematopoiesis and
frequent progression to AML (Nimer, 2008). Even in low-risk
MDS, clonal hematopoiesis already dominates at diagnosis,
and clones found in secondary AML originate from the MDS
stage of disease (Walter et al., 2012), highlighting the need to
specifically target theMDS-initiating clone. Previous studies pro-
vided support for del(5q)-MDS originating in hematopoietic stem
cells (HSCs; Nilsson et al., 2000), and in vitro and in vivo stem cell
(SC) assays have supported that rare CD34+CD38 cells
possess MDS-SC potential in low- to intermediate-risk MDS
(Nilsson et al., 2000, 2002; Pang et al., 2013; Tehranchi et al.,
2010). However, it remains to be established whether CD34+
CD38 cells are the only cells with SC potential in MDS because
other MDS progenitors, including distinct myeloid progenitor
subsets (Manz et al., 2002), have yet to be explored for theirMDS-SC potential (Agarwal, 2012; ASH-Workshop, 2010;
Nilsson et al., 2000; Pang et al., 2013). This is particularly relevant
because genomic lesions might potentially confer in vivo self-
renewal ability to otherwise short-lived myeloid progenitors.
We hypothesized that recently identified recurrent somatic
driver-mutations in low- to intermediate-risk MDS (Bejar et al.,
2011; Papaemmanuil et al., 2011, 2013; Yoshida et al., 2011)
should provide genetic tools to map the identity and fate of
MDS-propagating cells in patients in vivo.
RESULTS
Conservation of a Hierarchy of Molecularly and
Functionally Distinct Stem and Progenitor Cells in Low-
to Intermediate-Risk MDS
Because candidate CSCs/LSCs have frequently not been docu-
mented to be molecularly and functionally distinct or hierar-
chically related to other cancer/leukemic cells (Clevers, 2011;
le Viseur et al., 2008; Magee et al., 2012), a requirement for our
fate mapping approach to be informative, we first compared
the phenotypic, molecular and functional properties as well as
hierarchical relationships of Lineage (Lin)CD34+CD38CD90+
CD45RA candidate MDS-SCs with myeloid-restricted granulo-
cyte-macrophage and megakaryocyte-erythroid progenitors
(GMPs and MEPs, respectively; Majeti et al., 2007; Manz et al.,
2002).
In all investigated MDS cases (Table S1 available online),
phenotypically defined SCs, GMPs, MEPs, and common
myeloid progenitors (CMPs) were identified in agreement with
previous studies (Pang et al., 2013; Will et al., 2012). Each pop-
ulation was preserved at a low frequency despite high clonal
involvement (Figures 1A–1D). Absolute numbers of phenotypic
SCs and CMPs were expanded and GMPs reduced compared
to age-matched controls in isolated del(5q) MDS, other patients
with low- to intermediate-risk MDS with del(5q), and in non-
del(5q) MDS (Figure 1B). As reported recently for patients with
low-risk MDS (Pang et al., 2013), the suppression of GMPs
and increase in CMPs became clearer in del(5q) and non-
del(5q) MDS cases when assessed relative to the whole
LinCD34+CD38+ progenitor compartment (Figure 1B). This
analysis also revealed that MEPs were relatively suppressed in
non-del(5q) cases, but not in cases with del(5q) (Figure 1B). In
MDS cases with del(5q), the mean frequency of LinCD34+
CD38CD90+CD45RA SCs with del(5q) was as high as 93.7%
and 98.9% as determined by fluorescence in situ hybridization
(FISH) and sequencing, respectively (Figures 1C and 1D), sug-
gesting that del(5q) MDS-SCs outcompete normal HSCs. With
FISH, del(5q) was found to be high in CMPs, GMPs, MEPs,
and SCs, although slightly lower in GMPs and MEPs as deter-
mined by sequencing (Figure 1D), suggesting perhaps a slightCancer Cell 25, 794–808, June 16, 2014 ª2014 Elsevier Inc. 795
(legend on next page)
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Rare MDS-Propagating Cancer Stem Cells In Vivodisadvantage for generation or maintenance of del(5q) GMPs
and MEPs.
Because expression of cell surface antigens can be altered in
malignant hematopoiesis (le Viseur et al., 2008; Nguyen et al.,
2012), we also interrogated candidate MDS GMPs and MEPs
at the molecular and functional level. Candidate MDS GMPs
and MEPs displayed transcriptional expression profiles typical
of normal GMPs and MEPs (Figures 1E and 1F), and importantly
hadmyeloid- and erythroid-restricted lineage potentials, respec-
tively, in vitro (Figure 1G; Figures S1A and S1B). MDSCMPs (Fig-
ure 1A) expressed, as normal CMPs, both lineage programs,
which were low to absent in candidate MDS-SCs (Figure S1C).
Genes characteristic of normal HSCswere selectively expressed
in MDS LinCD34+CD38CD90+CD45RA SCs (Figure 1H). The
distinct molecular signatures of MDS SCs, GMPs, and MEPs
was further underpinned by a principle component analysis of
RNA sequencing data from purified stem and progenitor cells
(Figure 1I), demonstrating that SCs, GMPs, and MEPs from pa-
tients with MDS and age-matched normal controls clustered
together and distant from the other cell populations.
The ability to sustain long-term generation of MDS myeloid
progenitors in vitro (Hogge et al., 1996) was exclusively restricted
to LinCD34+CD38CD90+CD45RA cells and never observed
for MDS CMPs, GMPs, or MEPs (Figure 1J; Figure S1D).
Hierarchical Organization of MDS Stem and Progenitor
Cells
The distinct molecularly and functionally ‘‘lineage-restricted’’
signatures of MEPs and GMPs in all investigated MDS patients,
distinguishing them from the SC-signature of LinCD34+
CD38CD90+CD45RA SCs, implicated a hierarchical relation-
ship between LinCD34+CD38CD90+CD45RA SCs and
myeloid-restricted MEPs and GMPs. We further explored this
by investigating the ability of del(5q) LinCD34+CD38CD90+
CD45RA cells to replenish MEPs and GMPs. Because a high
fraction of human AMLs fail to reconstitute in xenograft assays
(Pearce et al., 2006), it is not surprising that also in most cases
of MDS the bone marrow (BM) cells fail to reconstitute im-
mune-deficient mice (Nilsson et al., 2002; Thanopoulou et al.,
2004), although in a recent study SCs from a few monosomy 7
MDS cases did engraft (Pang et al., 2013). In two del(5q) MDS
cases, with distinct MEPs, GMPs, and LinCD34+CD38CD90+
CD45RA candidate SCs (Figures 2A–2D; Figures S2A–S2C),Figure 1. Conservation of Molecularly and Functionally Distinct Hema
(A) FACS profiles of bonemarrow stem and progenitor cells in normal age-matche
non-del(5q) MDS (patient 68, bottom row) patients. Numbers indicate percentag
(B) Mean (SEM) stem/progenitor cell percentages in normal age-matched contro
RAEB-1 (n = 11) and non-del(5q) (n = 12) MDS in total BM (top row), and LinCD34
shown, *p < 0.05).
(C and D) Mean (SEM) del(5q)/trisomy 8 involvement as determined by FISH (C) (
(E and F) Mean (SEM) expression of myeloid (E) and erythroid (F) transcripts within
MDS (n = 4). *p < 0.05.
(G) Mean (SEM) myeloid and erythroid colony formation of purified GMPs and M
(H) Mean (SEM) expression of stem cell transcripts in normal age-matched BM
*p < 0.05; #, too low to depict.
(I) Principle component analysis (log-transformed) of normal control, del(5q) and n
population from one subject.
(J) Mean (SEM) LTC-CFC formation of purified stem (LinCD34+CD38CD90+CD
(n = 11).
See also Figure S1 and Table S1.multiple mice reconstituted with LinCD34+CD38CD90+
CD45RA cells (Figure 2E; Figure S2D). Not previously investi-
gated (Pang et al., 2013), but of decisive importance for propos-
ing that LinCD34+CD38CD90+CD45RA MDS cells might be
the only MDS-SCs, no reconstitution was observed with purified
CMPs, GMPs, MEPs, or CD34neg cells (Figure 2E; Figure S2D). In
both patients, LinCD34+CD38CD90+CD45RA cells only re-
constituted myelopoiesis long term, in agreement with B lym-
phopoiesis being suppressed in MDS (Figure 2F; Figure S2E;
Pang et al., 2013; Sternberg et al., 2005). Reconstituting
LinCD34+CD38CD90+CD45RA SCs sustained a high frac-
tion of CD34+ cells, including clonally involved LinCD34+
CD38CD90+CD45RA SCs, CMPs, GMPs, and MEPs (Figures
2G–2J, S2F, and S2G). Each stem/progenitor population regen-
erated from transplanted LinCD34+CD38CD90+CD45RA
cells revealed the same molecular signatures as the same
populations isolated directly from the patients (Figure 2K;
Figure S2H), establishing the ability of multipotent LinCD34+
CD38D90+CD45RA candidate MDS-SCs to replenish line-
age-restricted MDS progenitors.
Diverse Genetic Lesions in Low- to Intermediate-Risk
MDS Originate Exclusively in Rare
Lin–CD34+CD38–CD90+CD45RA– MDS-SCs
Recent studies have highlighted the inability of established CSC
assays to reliably identify tumor-propagating cells in patients
(Clevers, 2011; Kelly et al., 2007; Magee et al., 2012; Quintana
et al., 2008; Taussig et al., 2008), including in MDS (Agarwal,
2012; ASH-Workshop, 2010). Therefore, to validate MDS-SC
identity and activity within patients, we tracked the origin of
candidate driver mutations identified in bulk MDS BM cells.
Considering the short lifespan of normal myeloid progenitors
(Orkin and Zon, 2008), we argued that any stable mutations,
contributing to the MDS clone would have been acquired in cells
with self-renewal ability. From this it follows that if LinCD34+
CD38CD90+CD45RA cells are the only SCs in low- to interme-
diate-risk MDS, then the origin of every somatic mutation identi-
fied should be traced to this compartment (Figure 3A). If however
downstreamMDS progenitors have acquired self-renewal ability
upon acquisition of driver mutations, we should identify muta-
tions mapped to progenitors but not the upstream LinCD34+
CD38CD90+CD45RA SC compartment (Figures 3B and 3C).
Thus, we performed targeted screening for somatic DNAtopoietic Stem and Progenitor Cells in MDS
d control (top row), and representative del(5q) MDS (patient 1, middle row), and
es of total nucleated BM cells.
ls (n = 7) and low- to intermediate-risk isolated del(5q) (n = 9), del(5q) RCMD/
+CD38+ myeloid progenitor compartment (p values against normal controls are
del(5q) n = 5, +8 n = 2) and DNA sequencing (D) (n = 7), p values against SCs.
GMPs and MEPs from normal BM (n = 7), del(5q) MDS (n = 6), and non-del(5q)
EPs from del(5q) MDS (n = 17) and non-del(5q) MDS (n = 7).
(n = 7), del(5q) MDS (n = 6) and non-del5q MDS (n = 4) stem/progenitor cells.
on-del(5q) MDS-SCs, GMPs, andMEPs. Each dot represents the indicated cell
45RA) and progenitor cells from del(5q) MDS (n = 15) and non-del(5q) MDS
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Figure 2. Hierarchically Organized Stem and Progenitor Cells in del(5q) MDS
(A) FACS profiles and percentages of stem and progenitor cells in total BM from patient 37.
(B) Percentage del(5q) by FISH in purified stem and progenitor cells.
(C) Mean (SEM) LTC-CFC formation from purified stem/progenitor cells from patient 37. Three replicates per population.
(D) RNA sequencing analysis (reads per kilobase per million mapped reads, RPKM) of myeloid, erythroid, and stem cell transcripts in stem/progenitor cells.
(E) Mean (SEM) human (CD45+) engraftment in BM of NSG mice (two to three mice/cell population) transplanted with purified stem/progenitor cells from
patient 37.
(F) Mean (SEM) distribution ofmyeloid (CD15+/CD33+/CD66b+), B cell (CD19+), and CD34+ stem/progenitor cells inMDSSC-derived hCD45 cells (n = two to three
mice/donor).
(G) Stem and progenitor profiles in NSG BMof three mice 17–26 weeks after transplantation of purified SCs from patient 37. Percentages within total CD45+ cells
are shown.
(H) Mean percentages (SEM) of stem and progenitor cell populations within human CD45+ engrafted cells after transplantation of purified MDS-SCs into
NSG mice.
(I) Frequencies of del(5q) by FISH in MDS stem/progenitor cells purified from BM of NSG mice transplanted with purified MDS-SCs.
(J) Variant read frequencies for del(5q) and JAK2V617F in FACS sorted human myeloid (CD15+/CD33+/CD66b+) cells engrafted in NSG mouse 17 weeks after
transplantation of purified MDS LinCD34+CD38CD90+CD45RA SCs.
(K)Mean (SEM) gene expression in stem/progenitor cells purified fromBMof NSGmice transplantedwith purifiedMDS-SCs (n = two to three for each population).
See also Figure S2.
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myeloid malignancies (Bejar et al., 2011; Papaemmanuil et al.,
2011, 2013; Yoshida et al., 2011).798 Cancer Cell 25, 794–808, June 16, 2014 ª2014 Elsevier Inc.We identified 34 lesions, including del(5q) and mutations in
candidate driver-genes in bulk BM cells from 15 patients with
low- to intermediate-risk MDS (Figures 4A and 4B; Table S2),
Figure 3. Alternative Models for Sequential
Acquisition of Genetic Lesions in Hierar-
chically Organized MDS Stem and Pro-
genitor Cells
(A) Only LinCD34+CD38CD90+CD45RA SCs
have self-renewal (inherent; black arrow) ability;
and thus all somatic genetic lesions (a–d) can be
traced back to the rare SCs regardless whether
acquired in a linear (top) or branching (bottom)
pattern. As MDS-SCs replenish downstream pro-
genitors, mutations acquired in MDS-SCs are also
inherited by their downstream progenitors but
without conferring self-renewal potential.
(B) Self-renewal potential has been conferred (red
arrow) to a multipotent progenitor cell, which
therefore can acquire new and stable genetic
lesions (d) not found in the upstream SC
compartment but are found in downstream GMPs
and MEPs.
(C) Self-renewal potential has been acquired by
GMPs and MEPs in addition to the multipotent
progenitors thus allowing the occurrence of new
stable mutations (e) and (f) in GMPs and MEPs,
respectively.
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components of signaling pathways (JAK2, CSF3R), epigenetic
regulators (TET2, ASXL1), apoptosis regulators (TP53), and
spliceosome components (SF3B1, SRSF2, U2AF2, SRSF6).
Importantly, these mutations were typically present in the domi-
nant MDS clone as evidenced by amean variant allele frequency
(VAF) in whole BM cells of 30.8% (±3.3%; Figure 4B; Table S2),
demonstrating that they must indeed have originated in cells
actively propagating the MDS clone in vivo, fulfilling the strictest
definition of CSCs (Clevers, 2011; Magee et al., 2012). All these
genomic lesions were tracked back to the rare LinCD34+
CD38CD90+CD45RA SC compartment, including LinCD34+
CD38CD90+CD45RA-derived long-term colonies (Figure 4BCancer Cell 25, 794–8and S3) and NSG-reconstituting
LinCD34+CD38CD90+CD45RA cells
(Figure 2J). The mean VAF of these so-
matic mutations was as high as 43.4%
(±4.2%) in the LinCD34+CD38CD90+
CD45RASC compartment, and in all pa-
tients, the majority of individual long-term
colonies contained all identified genetic
driver-lesions, including del(5q) (Fig-
ure 4B). In agreement with this, based
on VAF for SNPs in the 5q common
deleted region (CDR), a mean of 97.3%
(±1.7%) of LinCD34+CD38CD90+
CD45RA SCs in these del(5q) patients
were del(5q) (Figure 4B; Table S2; Sup-
plemental Experimental Procedures).
Thus, the clonal advantage of del(5q)
MDS over normal hematopoiesis occurs
predominantly at the SC-level. As ex-
pected based on their hierarchical
relationship to LinCD34+CD38D90+
CD45RA MDS-SCs, identified muta-
tions were also found in purified GMPs and MEPs (Figure 4C).
Finally, even if not identified in the bulk BM cells, we screened
the purified Lin-CD34+CD38CD90+CD45RA SC compartment
for reported recurrent driver mutations in MDS (Bejar et al., 2011;
Papaemmanuil et al., 2011; Yoshida et al., 2011), but never iden-
tified a mutation in the LinCD34+CD38CD90+CD45RAMDS-
SC compartment, which was not also represented in bulk MDS
cells (P.S.W. and S.E.W.J., unpublished observations).
del(5q) Precedes Recurrent Driver Mutations in Isolated
del(5q) MDS
del(5q) is one of the most frequent cytogenetic aberrations in
MDS (Haase, 2008), observed in all subgroups of MDS including,08, June 16, 2014 ª2014 Elsevier Inc. 799
Figure 4. Mapping of Somatic Genetic Lesions to Rare and Distinct MDS Stem Cells
(A) del(5q) and genes with mutations in unfractionated (bulk) BM of specified MDS patients identified by targeted sequencing of recurrently mutated genes.
(B) Tracking of mutations identified in whole BM in (A) to LinCD34+CD38CD90+CD45RAMDS-SCs (stem) and individual SC-derived (LTC-CFC) clones; y-axis
numbers indicate percent variant reads for identifiedmutations. Formost patients typical LTC-CFCs produced fromCD34+CD38CD90+CD45RAMDS-SCs are
also shown, harboring all identified driver lesions as indicated by +.
(C) Percentage variant reads for identified mutations in purified GMPs and MEPs from the indicated patients.
See also Figure S3 and Table S2.
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Figure 5. With Exception of SF3B1-Mutated Cases with Ring Sideroblasts, del(5q) Precedes Recurrent Driver Mutations in Low- to
Intermediate-Risk MDS
(A) Number of low- to intermediate-risk del(5q) MDS cases analyzed by targeted (left) or exome (right) sequencing in which no or additional recurrent driver
mutations were identified.
(B) High confidence computational prediction of whether or not del(5q) occurred as the first identifiable genetic lesion in low- to intermediate-risk del(5q) MDS
cases with one or more candidate driver mutation(s). Error bars represent 95% CI.
(C) Summary of frequencies of del(5q) MDS patient subcategories in which del(5q) was identified as the only, or predicted to be the first or a secondary genetic
lesion. Inconclusive, overlap in 95% CI.
(D) Representative single cell (colony) analysis of reference (REF) and variant (VAR) reads for del(5q) and identified driver mutations in four patients with
overlapping 95% CI. Red indicates presence and blue absence of del(5q) and the specified mutations in individual colonies (each colony represented by vertical
columns).
See also Figure S4 and Table S3.
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del(5q) (previously termed 5q syndrome; Nimer, 2008). While
recent targeted sequencing studies of MDS patients (Bejar
et al., 2011; Fernandez-Mercado et al., 2013; Papaemmanuil
et al., 2013) and our data (Figure 4A) suggest that isolated
del(5q) MDS cases frequently harbor additional driver mutations,
the order of the mutation acquisition relative to del(5q) has not
been examined in detail.
To explore this further, we utilized three independent data sets
from low- to intermediate-risk MDS cases with del(5q): (1) in-
house targeted resequencing of 17 new cases; (2) computational
analysis of 36 cases from a previous study (Papaemmanuil et al.,
2013), including assessment of the frequencies of cells with
del(5q); and (3) nine cases with whole exome sequencing data
(Tables S1 and S3). In 19 (36%) of the 53 targeted resequencing
cases, no further recurrent driver mutations were identified, a
pattern confirmed in five of the nine whole exome-sequencedcases (Figure 5A; Table S3). In 12 of the additional 16 cases
with one ormore recurrent driver mutations and in which compu-
tational analysis allowed high confidence prediction (18 cases
did not; Figure S4A), del(5q) was predicted to have occurred
as the first genetic lesion, whereas in only four cases was a
recurrent driver mutation predicted to have preceded del(5q)
(Figure 5B). Notably, in all high-confidence cases where the
diagnosis was isolated del(5q) (n = 18) or RAEB-1/RCMD
(n = 10), del(5q) was predicted to be the first (or only) genetic
lesion, regardless of the identity or number of recurrent driver
mutations identified (Figure 5C).
Eighteen cases showed overlapping estimates of clonal frac-
tions for both del(5q) and the acquired mutations (Figure S4A).
To delineate these relationships, we performed single cell anal-
ysis in four of these cases, two isolated del(5q) and two
RCMD/RAEB-1, and were able to provide evidence that del(5q)
also preceded the identified driver mutations in each of theseCancer Cell 25, 794–808, June 16, 2014 ª2014 Elsevier Inc. 801
Figure 6. Mapping of Somatic Mutations to MDS Stem Cells in Sequential Samples in del(5q) MDS without Evidence of Disease Progression
(A) FACS profiles of SCs and progenitors in BM MNCs in serial samples at diagnosis (Diag) and months since diagnosis.
(B) del(5q) clonal involvement of LinCD34+CD38CD90+ MDS-SCs determined by FISH and targeted sequencing.
(legend continued on next page)
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was predicted not to be the initiating genetic lesion, del(5q)
was preceded by a recurrent mutation in SF3B1, and all of
these patients had been diagnosed with RARS or RCMD-RS
(Figures 5B and 5C).
Recently, compelling evidence for the existence of TIM3 pre-
AML SCs was reported, defined as HSCs harboring some but
not all recurrent driver mutations identified in the bulk AML,
and contributing to balanced lympho-myeloid reconstitution in
NSG mice (Jan et al., 2012). Here, we observed no long-term B
lymphoid reconstitution in NSG mice transplanted with CD34+
BM cells from nine MDS cases with del(5q) (Figures S4B and
S4C), similar to a recent study which also found exclusive
long-term myeloid and no B cell contribution from HSCs purified
from low-risk MDS patients (Pang et al., 2013). Also, in four
del(5q)-MDS patients in which we separated the LinCD34+
CD38CD90+ SC compartment into TIM3+ and TIM3 subsets
(Figure S4D), we explored their ability to produce myeloid and
B cells in vitro. Whereas LinCD34+CD38CD90+ SCs from
normal age-matched controls efficiently produced B and
myeloid cells, TIM3+ as well as TIM3 SCs from the investigated
del(5q) cases produced exclusively myeloid cells (Figure S4E).
Thus, in agreement with our findings compatible with del(5q)
being the initiating and potentially also the only required genetic
lesion for development of isolated del(5q)-MDS, we found no
evidence for pre-MDS SCs in low- to intermediate-risk MDS
with del(5q).
Evolution of Genetic Lesions in del(5q) MDS Stem Cells
during Disease Progression
We next monitored rare LinCD34+CD38CD90+CD45RA
MDS-SCs in sequential BM samples to gain insights into the
potential genomic evolution and impact of somatic mutations
on the MDS stem and progenitor cell hierarchy, in stable disease
aswell as prior to disease progression (see Supplemental Exper-
imental Procedures and Table S1). Moreover, to establish amore
complete and unbiased picture of somatic exonic mutations,
and towhat degree diversemutations (recurrent drivermutations
and nonrecurrent, most likely passenger mutations) in the active
MDS clones could all be backtracked to the CD34+CD38CD90+
MDS-SC compartment, we exome-sequenced bulk BM cells of
four patients with del(5q) (Figures 6 and 7).
Two of the patients (patients 2 and 39) had stable disease, and
exome-sequencing was performed at diagnosis as well as 30–
32 months later when they remained transfusion-independent
on long-term lenalidomide. At this time, the MDS-SCs, MEPs,
and GMPs retained distinct phenotypic, functional, and molecu-
lar signatures (Figures 6A–6C; Figure S5). Exome-sequencing
identified no (patient 2) and two (patient 39; Figure 6D) recurrent
driver mutations, and in both cases a number of predicted so-
matic passenger mutations (Table S4), which in both patients(C) Mean (SEM) LTC-CFCs generated from LinCD34+CD38CD90+ MDS-SCs,
(D) Frequency of exome variant reads in BM MNC. Dotted lines represent 5% va
(E) Presence (red) and absence (blue) of variant reads for identified mutations in S
from LinCD34+CD38CD90+ cells). Synonymous mutations are indicated by no
(F) del(5q) and mutational status in representative individual LinCD34+CD38CD
Colonies shown at the furthest right were analyzed for presence of recurrent driv
LTC-CFC.
See also Figure S5 and Tables S4 and S5.could all be back-tracked to the LinCD34+CD38CD90+
MDS-SC compartment, including LTC-CFCs, already at diag-
nosis and none had been eliminated despite the patients being
in clinical remission 30–32 months later (Figure 6E and
Tables S4 and S5). Sequencing of individual long-term colonies
derived from LinCD34+CD38CD90+ SCs established in both
patients that all identified mutations had occurred in a linear
manner (Figure 6F, Table S5). Notably, neither of these two pa-
tients have transformed to AML in the 2–4 years since the last
analysis.
In a third, isolated del(5q) case (patient 3) with distinct SC and
progenitor signatures (Figures 7A–7C, S6), who transformed to
AML only 13 months later (no AML sample available), exome-
sequencing of BM cells (23 months after diagnosis) obtained
when the patient was responding well to lenalidomide, identified
six somatic mutations, including a recurrent TP53 mutation,
associated with poor prognosis (Ja¨dersten et al., 2011). None
of these could be confidently identified in bulk BM cells at diag-
nosis neither by exome (Figure 7D; Table S6) nor targeted (Table
S7) sequencing. However, all identified mutations could be
backtracked to the MDS-SC compartment at 23 months (Fig-
ure 7E), and individual LTC-CFC analysis confirmed that
del(5q) along with a nonrecurrent MINA mutation preceded the
other mutations, including the TP53 mutation (Figures 7F, 7G,
S3, and S6; Table S7).
A fourth patient with isolated del(5q) was analyzed before and
following lenalidomide treatment, as well as at disease progres-
sion preceding AML transformation (Figures 7H–7Q; Figure S6;
Table S1). Exome-sequencing identified 15 somatic mutations
at disease progression, including a recurrent JAK2V617F and
a recurrent TP53mutation. The JAK2V617F and ten other nonre-
current mutations were confidently identified in the bulk BM cells
as well as in purified LinCD34+CD38CD90+CD45RA SCs in
the initial BM sample more than 9 years earlier (Figures 7K and
7L; Tables S6 and S7). Despite reduced transfusion needs on le-
nalidomide treatment, 5 years later a previously undetectable
recurrent TP53 mutation was now detected in bulk BM cells as
well as in LinCD34+CD38CD90+CD45RA SCs (Figures 7L–
7N; Tables S6 and S7). The patient later lost lenalidomide
responsiveness and progressed to higher risk MDS (RAEB-1;
9%BMblasts), at which time exome-sequencing identified three
additional mutations (Figures 7K–7N; Tables S6 and S7).
Whereas the origin of the new IKZF1 and SPRED2 mutations
as other mutations could be mapped to purified LinCD34+
CD38CD90+ SCs as well as SC-derived LTC-CFCs, the last
mutation (PIFO) detected in 8.5% and 5.8% reads in whole BM
with exome and targeted sequencing, respectively (Figures 7K
and 7N; Tables S6 and S7), was undetectable in purified
LinCD34+CD38CD90+ SCs and SC-derived LTC-CFCs (Fig-
ures 7L–7M; Table S7). This suggested that the PIFO mutation
might have occurred in a progenitor population outside theGMPs, and MEPs.
riant read cut-off. Recurrent driver mutations are indicated in bold.
Cs (purified LinCD34+CD38CD90+ cells and/or individual LTC-CFCs derived
specified amino acid change.
90+-derived long-term colonies (gray, nonconclusive; orange, primer failure).
er mutations only. Each vertical column shows mutation status in an individual
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have acquired self-renewal potential. Because MEPs and a
LinCD34+CD38CD90 multipotent progenitor (MPP) popula-
tion (Majeti et al., 2007) had expanded at the time of progression
(Figure 7H), we also performed targeted resequencing of these
progenitor populations (Figures 7O and 7P), and identified, at
progression but not in the preceding sample, PIFO variant reads
at similar high frequencies as for the TP53 mutation (Figures 7O
and 7P; Table S7). These findings were compatible with the pre-
ceding recurrent TP53 mutation that occurred in the LinCD34+
CD38CD90+ MDS-SC-compartment, conferring progenitor
self-renewal and expansion at disease progression, as signified
by the high reads for the predicted silent PIFO mutation exclu-
sively outside the LinCD34+CD38CD90+ compartment, thus
here acting as a molecular marker for acquired self-renewal
potential outside the LinCD34+CD38CD90+ SC compartment.
In further support of this, single cell analysis confirmed themutu-
ally exclusive relationship of the IKZF1 (and SPRED2) and PIFO
mutations, representing distinct del(5q) subclones, which prior
to this branching had sequentially acquired recurrent del(5q),
JAK2 V617F, and TP53 genetic lesions (Figures 7Q and 7R;
Table S7). Notably, this patient transformed to AML 7 months
later (from which time no BM or blood sample was available).
DISCUSSION
Efforts to identify distinct human CSCs have become a major
focus in translational and clinical cancer research. Conse-
quently, it was a considerable setback, yet to be resolved,
when many studies established the inability of in vivo CSC
assays to reliably uncover the tumorigenic potential of many
cancer cell populations, including in hematological malignancies
(Clevers, 2011; Kelly et al., 2007; le Viseur et al., 2008; Magee
et al., 2012; Pearce et al., 2006; Quintana et al., 2008; Taussig
et al., 2008). Moreover, the identification of distinct human
CSCs exerting their potential in patients (Clevers, 2011; Magee
et al., 2012), including in MDS (Agarwal, 2012; ASH-Workshop,
2010), has remained elusive.
Here, we provide evidence of rare LinCD34+CD38CD90+
cells functioning as MDS-SCs in patients with low- to intermedi-
ate-risk MDS in vivo. LinCD34+CD38CD90+ MDS-SCs are
molecularly and functionally distinct from clonally involvedFigure 7. Genetic Evolution in MDS Stem and Progenitor Cells Preced
Stem and progenitor cell characterization, and mutational status in sequential
19 (H–R).
(A and H) FACS profiles of SCs and progenitors in BM MNCs in serial samples (a
(B and I) del(5q) clonal involvement of LinCD34+CD38CD90+CD45RA MDS-S
(C and J) Mean (SEM) LTC-CFCs generated from LinCD34+CD38CD90+CD45
(D and K) Frequency of exome variant reads in BMMNC at diagnosis and 23 mont
read cut-off. Recurrent driver mutations are indicated in bold.
(E and L) Presence (red) and absence (blue) of variant reads for identified m
nonconclusive).
(F and M) del(5q) and mutational status in representative individual LinCD34+CD
mutation status in an individual LTC-CFC.
(N–Q) Presence or absence of TP53, IKZF1, SPRED2, and PIFOmutations in BM
and MPPs; percent variant reads at 170 months, are shown to the right, and from
MEPs (Q).
(G and R) Proposed sequential acquisition of genetic events based on analysis o
clones.
See also Supplemental Experimental Procedures, Figure S6, and Tables S6 andGMPs and MEPs. Importantly, LinCD34+CD38CD90+ cells
replenish GMPs and MEPs, establishing their hierarchical rela-
tionship. Although it cannot formally be ruled out, this hierarchi-
cal relationship argues against the possibility of driver mutations
occurring outside the LinCD34+CD38CD90+ SC compartment
inducing self-renewal potential in progenitors and consequently
a LinCD34+CD38CD90+ SC-immunophenotype. Together
with these findings, our backtracking of all identified somatic
genetic lesions in the bulk BM from patients with MDS to
LinCD34+CD38CD90+ MDS-SCs provides evidence for the
existence of rare human CSCs in vivo, and that these are the
only MDS-SCs in vivo in low-risk MDS. This finding has wide
clinical implications, highlighting that propagation and evolution
of genetic lesions in theMDS clone is strictly dependent on a rare
SC at early stages of MDS. In all investigated cases, the candi-
date driver mutations were all part of the same dominating SC
clone, suggesting that they provideMDS-SCswith a competitive
advantage over normal HSCs and the parental MDS clone, but
even in combination fail to confer self-renewal potential to down-
stream progenitors. Even at diagnosis, MDS-SCs typically
harbored multiple somatic mutations, including recurrent driver
mutations, acquired in a linear, rather than branching, manner
within the LinCD34+CD38CD90+ SC compartment.
Sequencing analysis provided insights into the relationship
between del(5q) and somatically acquired mutations, in partic-
ular in isolated del(5q) MDS. In more than 50% of isolated
del(5q) cases, no recurrent driver mutation was identified by tar-
geted or exome sequencing. Although our sequencing strategies
may have missed recently identified recurrent mutations in MDS
(Klampfl et al., 2013; Nangalia et al., 2013; Papaemmanuil et al.,
2013) and additional significant mutations are likely to be identi-
fied in the future, this is unlikely to explain why the fraction of
cases without identified recurrent driver mutations is higher in
patients with isolated del(5q) than in other groups with low- to
intermediate-risk MDS and del(5q). In further support of del(5q)
being the initiating genomic lesion in isolated del(5q) MDS, in
all cases with at least one identifiable recurrent driver mutation
where high confidence sequence of event prediction could be
made, del(5q) preceded the acquired mutations. These findings,
combined with our lack of evidence for a pre-MDS SC popula-
tion, and the absence of deletions involving the 5q CDR in a
large-scale screen for frequent copy number variations in theing AML Transformation
BM samples, purified MDS-SCs, and LTC-CFCs from patients 3 (A–G) and
t diagnosis and months since diagnosis).
Cs.
RA MDS-SCs, GMPs and MEPs.
hs (patient 3) and at 170 months (patient 19). Dotted lines represent 5% variant
utations in LinCD34+CD38CD90+ SCs and/or individual LTC-CFCs (gray,
38CD90+CD45RA-derived long-term colonies. Each vertical column shows
MNCs (N), MEPs (O), and MPPs (P); two replicate samples analyzed for MEPs
representative single cell clones from short-term expanded SCs, MPPs, and
f sequential samples, individual LTC-CFC, and single-cell SC, MPP, and MEP
S7.
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compatible with del(5q) being an initiating and potentially also
the only genomic lesion required to develop the distinct clinical
entity of isolated del(5q) MDS. However, further genomic
analysis of patients and genetic modeling will be required to
unequivocally establish if del(5q) is sufficient to induce isolated
del(5q) MDS. Recent studies have shed some light on candidate
genes within the 5q CDR responsible for causing some of the
phenotypes associated with isolated del(5q) MDS (reviewed in
Komrokji et al., 2013). It will be important to explore to what
degree haploinsufficiency of the same or distinct genes in the
5q CDR is responsible for the competitive advantage of del(5q)
over normal HSCs.
The only low- to intermediate-risk cases in which del(5q) was
not the first identified genomic lesion were four cases of ring
sideroblastic anemia in which del(5q) was preceded by a recur-
rent SF3B1 mutation. Intriguingly, just as del(5q) might largely
define the phenotype of isolated del(5q) MDS, SF3B1mutations
are thought to be an early and potentially initiating event defining
ring sideroblastic anemia (Papaemmanuil et al., 2011; Yoshida
et al., 2011).
Although limited to four MDS cases with del(5q), tracking
CD34+CD38CD90+MDS-SCs and progenitors by sequential
genomic and functional analysis provided insights into the land-
scape of somatic mutations in stable disease and preceding
disease progression, and how they might impact on the MDS
stem and progenitor cell hierarchy. In two patients with del(5q)
who remained transfusion-independent on long-term lenalido-
mide treatment, the majority of LinCD34+CD38CD90+ SCs
remained part of the del(5q) clone, and no mutations present at
diagnosis had been eliminated, nor had any new been acquired.
This suggests that in patients with low-risk del(5q) with stable
disease, the landscape of somatic mutations in MDS-SCs may
be quite stable. However, in two other patients with low-risk iso-
lated del(5q) MDS who later transformed to AML, additional mu-
tations were identified in the SC-compartment while BM blasts
remained <5%. In both cases, a recurrent TP53 mutation
emerged, conferring worse prognosis (Ja¨dersten et al., 2011).
When one of these patients progressed to RAEB-1 with a higher
blast count, additional mutations were mapped to the MDS-SC
compartment. However, a predicted passenger mutation
(PIFO) could not be mapped to the SC compartment but was
instead observed at a high frequency in expanded progenitor
compartments along with the preceding TP53 mutation,
compatible with acquisition of self-renewal potential by the
MPPs (or a progenitor positioned between the LinCD34+
CD38CD90+CD45RA and MPP compartment) at the time of
disease progression following acquisition of a TP53 mutation.
Although limited to one patient, and awaiting further validation
and genetic modeling, this finding provides compelling in vivo
evidence in support of sequentially acquired driver genomic
lesions (del(5q), JAK2V617F, and TP53) in a small human CSC
compartment, eventually conferring self-renewal and thus
expansion-potential to downstream progenitors. This is of
considerable relevance to the observed disease progression
and subsequent AML transformation frequently seen in MDS pa-
tients, and in agreement with previous studies implicating that
AML frequently contains candidate LSCswith a progenitor rather
than SC phenotype (Goardon et al., 2011; Jamieson et al., 2004).806 Cancer Cell 25, 794–808, June 16, 2014 ª2014 Elsevier Inc.From the outset it could not be excluded that progenitors posi-
tioned between the LinCD34+CD38CD90+ SCs and myeloid-
restricted MEPs and GMPs, including MPPs, might also act as
MDS-SCs in vivo. However, backtracking of all identified so-
matic mutations to the Lin-CD34+CD38-CD90+ SC compartment
in patients with low-risk MDS suggests that this is rarely the case
in early MDS. Our conclusions are limited by the number of
patients analyzed, and the fact that patients with MDS are highly
heterogeneous with regard to their number and type of recurrent
driver mutations (Papaemmanuil et al., 2013). Recent studies in
mice have implicated the existence of lineage-biased and
perhaps even platelet-myeloid-restricted HSCs (Sanjuan-Pla
et al., 2013; Yamamoto et al., 2013).When corresponding human
HSC subsets can be identified, it will be of considerable interest
to determine whether mutational targeting of such myeloid-
biased or restricted stem cells may explain the largely myeloid-
restricted phenotype of MDS.
Our findings suggest that MDS therapies with curative
ambitions may best be applied in early MDS when MDS-
SCs remain restricted to rare LinCD34+CD38CD90+ cells.
Although possessing properties predicting that they will be chal-
lenging to target effectively (Tehranchi et al., 2010), the identifica-
tion of distinct and rare MDS-SCs will facilitate identification of
molecular targets and development of targeted therapies to elim-
inateMDS-SCs in a disease currently notoriously difficult to cure.
Although CSCs inmore aggressive human cancersmay not be
rare, the distinct functional and molecular identity of MDS-SCs
established here highlights the critical importance of continued
efforts to identify in vivo, monitor and therapeutically target
distinct CSCs, as their elimination should not only be essential
but, in principle, also sufficient for development of curative
cancer therapies.
EXPERIMENTAL PROCEDURES
Patients
Patients with low- to intermediate-risk MDS were included (see Table S1 for
clinical details). BM from age-matched healthy individuals was always used
for controls unless otherwise specified. All patients provided written informed
consent and the study was approved by the ethics committees at the Karolin-
ska Institute, The Norwegian Radiumhospital, Aarhus University Hospital,
University of Pavia, Hoˆpital Avicenne Assistance Publique-Hoˆpitaux de Paris
(AP-HP), University of Dundee, St. James Hospital, University of Oxford,
University of New South Wales and Ska˚ne University Hospital.
Flow Cytometry
Stem/progenitor analysis/isolation in BM mononuclear cells was performed
as described (Tehranchi et al., 2010) and outlined in the Supplemental
Experimental Procedures.
Gene Expression Analysis
Gene expression was analyzed by Fluidigm Dynamic Arrays and global RNA
sequencing (Supplemental Experimental Procedures).
FISH
Interphase FISH for del(5q) and +8 was performed as described in the
Supplemental Experimental Procedures.
In Vitro Assays
Detailed methods for colony-forming cell (CFC), long-term-culture-CFC
(LTC-CFC), and B cell potential, as well as short-term expansion of single cells
are described in the Supplemental Experimental Procedures.
Cancer Cell
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Cells were transplanted into irradiated NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG)
mice, and analyzed as outlined in the Supplemental Experimental Procedures.
Experiments were performed in accordance with UK Home Office Project
License 30/2570.
DNA Mutational Analysis
Targeted sequencing and exome sequencing for detection, tracking and
quantification of genetic lesions were performed and analyzed as described
in the Supplemental Experimental Procedures. Briefly, mutations were identi-
fied in bulk MDS BM by targeted sequencing of coding region of genes
recurrently mutated in myeloid malignancies using a HaloPlex kit (Agilent
Technologies) or custom designed RNA baits (Papaemmanuil et al., 2013),
as well as by whole exome sequencing using a SureSelect kit (Agilent
Technologies) according to the manufacturer’s instructions. Mutations were
back-tracked to stem and progenitor compartments by targeted sequencing,
either using HaloPlex kit or Access Array chip (Fluidigm) with custom designed
PCR primers.
Statistical Analysis
Statistical analysis was performed using Graphpad Prism 6 software. For
individual comparisons nonparametric Mann-Whitney test was used and
p values less than 0.05were considered significant. Details of the bioinformatic
analysis are included in the Supplemental Experimental Procedures.
ACCESSION NUMBERS
The Gene Expression Omnibus accession number for the RNA sequencing
reported in this paper is GSE55689 and the sequence read archive accession
number for the DNA sequencing reported in this paper is SRP039353.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
six figures, and seven tables and can be found with this article online at
http://dx.doi.org/10.1016/j.ccr.2014.03.036.
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